Metabolics — Request for Proposals

RFPCAT2-13-MET-202

RFPCAT2-13-MET-203

Diabetes continues to be an ever-increasing public health problem throughout the world. In 2000, slightly more than 4% of U.S. adults had diabetes. Today, that figure has risen to nearly 11%, or approximately 27 million people, according to the American Diabetes Association (ADA) and the Centers for Disease Control and Prevention (CDC). By 2050, that figure is expected to rise to 33% of the population. Approximately 1.9 million new cases of diabetes are diagnosed each year. As its prevalence increases, diabetes continues to be a leading cause of disability and death in the United States. In recent years, diabetes has directly claimed more than 71,000 lives and contributed to about 160,000 additional deaths annually.

It has been well-established that patients with type 2 diabetes (T2D) are at increased risk for cardiovascular disease (CVD), including coronary heart disease, myocardial infarction, and stroke. Patients with CVD and T2DM have a worse prognosis than those with CVD and no diabetes, and derive less benefit from multiple preventive and interventional advances compared with non-diabetic patients with CVD. In fact, individuals with diabetes are two to four times more likely than those without to die from cardiovascular disease, which accounts for 65% of deaths in patients with diabetes. T2DM is associated with increased CVD via multiple pathologic effects, including accelerated atherosclerosis, and abnormalities in inflammatory pathways and endothelial, myocardial, and platelet function

In addition, T2DM and CVD may have common antecedents - T2DM and CVD share multiple risk factors:

• Non-modifiable risk factors include age, sex, Race/Ethnicity, Family history
• Modifiable Risk Factors include obesity, Sedentary lifestyle, Diet and Smoking

1. Describe the pathophysiological correlation between Type 2 Diabetes (T2D) and Cardiovascular (CV) effects both in the short- and long-term
2. Understand biological mechanisms of disease that potential contribute to cardiovascular (CV) Risk in Type 2 Diabetes
3. Evaluate the clinical landscape of T2DM and cardiovascular risk.

The content and/or the format of the CME/CE activity and its related materials must be designed in such a way that it addresses the educational needs of health care professionals and, if appropriate, tools/aids that can help health care practitioners communicate with or better manage their patients.

Presentations and content must give a scientifically sound, fair and balanced overview of new and emerging therapeutic options currently available or in development to manage or prevent this disease.

The accrediting provider and, if applicable, the medical education provider (MEP) or other third party vendors executing the activities are expected to comply with current ethical codes and regulations. They must have a conflict-of-interest policy in place, identify and/or resolve all personal conflicts of interest from presenters or staff developing the content of the activity prior to delivery of the program, and must have an adequate firewall in place if they are performing promotional activities and providing/accrediting independent medical education.

If your organization wishes to submit an educational grant request, please click here to access the online application.

Please use RFP Code “RFPCAT2-13-MET-202” in the beginning of the title of your application.

The kidney has a key role in regulating glucose levels — by mediating the reabsorption of glucose back into the plasma — following filtration of the blood such that no glucose is lost. The sodium-glucose cotransporter 2 (SGLT2), a high capacity, low affinity transporter is found mainly in the S1 segment of the proximal tubule and is responsible for approximately 90% of reabsorbed glucose by the kidney. Under normal circumstances in individuals without T2DM, the renal glomeruli filter approximately 180 g of glucose per day, virtually all of which is reabsorbed by the proximal tubules via an insulin independent process. In the context of type 2 diabetes (T2DM), this process contributes to sustained elevated serum glucose levels, as patients with T2DM have an increased capacity for renal glucose reabsorption. Recent clinical data suggest that SGLT2 inhibitors reduce hyperglycemia by increasing urinary excretion of glucose. With new advances in T2DM, there is an increased need for healthcare professionals to understand the existing clinical data on this topic.

The content and/or the format of the CME/CE activity and its related materials must be designed in such a way that it addresses the educational needs of health care professionals and, if appropriate, tools/aids that can help health care practitioners communicate with or better manage their patients.

Presentations and content must give a scientifically sound, fair and balanced overview of new and emerging therapeutic options currently available or in development to manage or prevent this disease.

The accrediting provider and, if applicable, the medical education provider (MEP) or other third party vendors executing the activities are expected to comply with current ethical codes and regulations. They must have a conflict-of-interest policy in place, identify and/or resolve all personal conflicts of interest from presenters or staff developing the content of the activity prior to delivery of the program, and must have an adequate firewall in place if they are performing promotional activities and providing/accrediting independent medical education.

If your organization wishes to submit an educational grant request, please click here to access the online application.

Please use RFP Code “RFPCAT2-13-MET-203” in the beginning of the title of your application.

Bays, H. Curr Med Res Opin (2009) 25:671-681.

Gerich, J. Diabetic Med (2010) 27:136-142.

Chao and Henry. Nat Rev Drug Discov (2010) 9:551-559